{
    "id": "22759eaf-980b-4683-abbf-317e56323541",
    "indications": "Sucralfate Oral Suspension is indicated in the short-term (up to 8weeks) treatment of active duodenal ulcer.",
    "contraindications": "The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach.\n                        Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension.\n                        While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.",
    "warningsAndPrecautions": "Sucralfate Oral Suspension, 1 g/10 mL is a pink suspension with cherry flavor supplied in the following dosage forms:\n                  NDC 0904-7470-66: 10 mL unit dose cup.  Case contains 20 unit-dose cups of 10 mL (NDC 0904-7470-56), packaged in 2 trays of 10 unit-dose cups each, 30 unit-dose cups of 10 mL (0904-7470-01), packaged in 3 trays of 10 unit-dose cups each, 40 unit-dose cups of 10 mL (NDC 0904-7470-18), packaged in 4 trays of 10-unit-dose cups each, 50 unit-dose cups of 10 mL (NDC 0904-7470-95), packaged in 5 trays of 10 unit-dose cups each and 100 unit-dose cups of 10 mL (NDC 0904-7470-72), packaged in 10 trays of 10 unit-dose cups each.\n                  \n                     SHAKE WELL BEFORE USING.  AVOID FREEZING.\n                  \n                  Store at controlled room temperature 20º to 25ºC (68º to 77ºF); excursions permitted between 15º to 30ºC (59º to 86ºF).  [See USP Controlled Room Temperature].\n                  Rx Only\n                  \n                     Distributed by:\n                     \n                     MAJOR® PHARMACEUTICALS\n                     Indianapolis, IN  46268\n                  \n                      \n                  \n                  \n                     R02/24",
    "adverseReactions": "Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.",
    "ingredients": [
        {
            "name": "SUCRALFATE",
            "code": "XX73205DH5"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLCELLULOSE, UNSPECIFIED",
            "code": "Z944H5SN0H"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        }
    ],
    "organization": "Major Pharmaceuticals",
    "name": "Sucralfate",
    "effectiveTime": "20250502"
}